LIBTAYO® (cemiplimab-rwlc) logo

LIBTAYO is a human IgG4
anti–PD-1 monoclonal antibody1

LIBTAYO was generated using
VelocImmune® technology2

  • VelocImmune is a unique technology for producing human monoclonal antibodies3
  • Efficiently creates a large quantity of optimized antibody drug candidates3
  • Creates high-affinity antibodies to therapeutic targets3

LIBTAYO mechanism of action (MOA)

Inactive T-cell resulting from the interaction of the PD-1 receptor on tumor cell

Tumor-immune evasion

T-cell inactivation can result from interaction of the PD-1 receptor on tumor-infiltrating
T cells with its ligands, PD-L1 and PD-L2, expressed on tumor cells.1

T-cell activity restored

LIBTAYO binds to PD-1 on T cells, blocking its interaction with PD-L1 and PD-L2 on tumor cells, helping to restore the antitumor T-cell response.1

LIBTAYO can help restore T-cell activity
  • IgG4=immunoglobulin G4; PD-1=programmed death receptor-1; PD-L1=programmed death ligand 1; PD-L2=programmed death ligand 2.